Next 10 |
2024-07-17 17:51:42 ET More on Cardinal, Cencora, McKesson McKesson Corporation: An Interesting Health Giant With A Hidden Gem Cardinal Health: Growing Into The Valuation Cencora: Potential Exists, But Ambiguous Valuations And Data Breach Risks Are Concerning ...
2024-07-16 05:30:00 ET Summary TimesSquare Capital U.S. Small Cap Growth portfolio outperformed the Russell 2000® Growth Index in the second quarter. The portfolio outperformed the Russell Midcap Growth Index in the second quarter. Pulling back by -27% was Legend Biotech,...
2024-07-09 09:00:37 ET Summary This article updates one I wrote in August 2022, which was based on a template article by David Van Knapp published in June 2020. I use an adapted quality scoring system to assess the quality of dividend growth stocks. The system employs six qual...
UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMD Initial commercial launches of LYTENAVA™ (bevacizumab gamma) in the EU and UK anticipated in calendar Q1 2025...
Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2024 on Wednesday, July 31, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on July 3...
2024-07-04 06:08:53 ET Summary McKesson Corporation is a large player in the medical space, with a market capitalization of $75.86 billion. The company has shown attractive top-line growth, but bottom-line results have been disappointing. The most interesting segment of the bu...
2024-07-03 22:30:00 ET Summary Closing out the first half of 2024, the S&P 500 Total Return Index (which includes dividend reinvestment) is up an incredible +15.3%. According to Apollo asset management, Nvidia accounted for a record-breaking 34.5% of the total return in the S&...
2024-07-02 13:00:00 ET Summary 21 new analysts joined in June and are highlighted today. Each is introduced with some details on their first investment thesis on Seeking Alpha and their background. Analysts cover a range of sectors including biotech, technology, consumer staples, ...
2024-06-30 07:31:30 ET Summary Cencora, Inc. shows potential undervaluation per DCF analysis, but comparable companies (comps) analysis indicates possible overvaluation. Cencora operates globally in pharmaceutical distribution and faces stiff competition in a consolidated industry...
2024-06-29 14:45:00 ET We are just two weeks away from the second quarter earnings season, and the lull phase of the first quarter reporting is slowly coming to an end. In the last week of June, eight S&P companies disclosed their earnings. Here is a quick glance at the financial result...
News, Short Squeeze, Breakout and More Instantly...
CoreSite Realty Corporation Company Name:
COR Stock Symbol:
NYSE Market:
CoreSite Realty Corporation Website:
UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMD Initial commercial launches of LYTENAVA™ (bevacizumab gamma) in the EU and UK anticipated in calendar Q1 2025...
Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2024 on Wednesday, July 31, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on July 3...
VANCOUVER, BC / ACCESSWIRE / June 27, 2024 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF)(WKN:A116E1 ) (" Camino " or the " Company ") is pleased to announce that it has been granted exclusivity to complete due diligence and negotiate documentation by August 31, 2024, to acquire (the ...